Increase in Tumor Control and Normal Tissue Complication Probabilities in Advanced Head-and-Neck Cancer for Dose-Escalated Intensity-Modulated Photon and Proton Therapy

被引:17
|
作者
Jakobi, Annika [1 ]
Luehr, Armin [1 ,2 ,3 ]
Stuetzer, Kristin [1 ]
Bandurska-Luque, Anna [1 ,4 ]
Loeck, Steffen [1 ]
Krause, Mechthild [1 ,2 ,3 ,4 ,5 ]
Baumann, Michael [1 ,2 ,3 ,4 ,5 ]
Perrin, Rosalind [1 ]
Richter, Christian [1 ,2 ,3 ,4 ,5 ]
机构
[1] Tech Univ Dresden, Helmholtz Zentrum Dresden Rossendorf, Univ Hosp Carl Gustav Carus, OncoRay Natl Ctr Radiat Res Oncol,Fac Med, D-01062 Dresden, Germany
[2] German Canc Consortium DKTK, Dresden, Germany
[3] German Canc Res Ctr, Heidelberg, Germany
[4] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Fac Med, Dept Radiat Oncol, D-01062 Dresden, Germany
[5] Helmholtz Zentrum Dresden Rossendorf, Inst Radiooncol, Dresden, Germany
来源
FRONTIERS IN ONCOLOGY | 2015年 / 5卷
关键词
photon radiotherapy; proton radiotherapy; tumor control probability; normal tissue complication probability; head-and-neck cancer; SQUAMOUS-CELL CARCINOMAS; RADIATION ONCOLOGY; RESPONSE ANALYSIS; CHEMO-IMRT; RADIOTHERAPY; HYPOXIA; BOOST; RADIOCHEMOTHERAPY; DYSPHAGIA; PATTERNS;
D O I
10.3389/fonc.2015.00256
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Presently used radiochemotherapy regimens result in moderate local control rates for patients with advanced head-and-neck squamous cell carcinoma (HNSCC). Dose escalation (DE) may be an option to improve patient outcome, but may also increase the risk of toxicities in healthy tissue. The presented treatment planning study evaluated the feasibility of two DE levels for advanced HNSCC patients, planned with either intensity-modulated photon therapy (IMXT) or proton therapy (IMPT). Materials and methods: For 45 HNSCC patients, IMXT and IMPT treatment plans were created including DE via a simultaneous integrated boost (SIB) in the high risk volume, while maintaining standard fractionation with 2 Gy per fraction in the remaining target volume. Two DE levels for the SIB were compared: 2.3 and 2.6 Gy. Treatment plan evaluation included assessment of tumor control probabilities (TCP) and normal tissue complication probabilities (NTCP). Results: An increase of approximately 10% in TCP was estimated between the DE levels. A pronounced high-dose rim surrounding the SIB volume was identified in IMXT treatment. Compared to IMPT, this extra dose slightly increased the TCP values and to a larger extent the NTCP values. For both modalities, the higher DE level led only to a small increase in NTCP values (mean differences <2%) in all models, except for the risk of aspiration, which increased on average by 8 and 6% with IMXT and IMPT, respectively, but showed a considerable patient dependence. Conclusion: Both DE levels appear applicable to patients with IMXT and IMPT since all calculated NTCP values, except for one, increased only little for the higher DE level. The estimated TCP increase is of relevant magnitude. The higher DE schedule needs to be investigated carefully in the setting of a prospective clinical trial, especially regarding toxicities caused by high local doses that lack a sound dose response description, e.g., ulcers.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Comparison of CT- and FDG-PET-defined gross tumor volume in intensity-modulated radiotherapy for head-and-neck cancer
    Paulino, AC
    Koshy, M
    Howell, R
    Schuster, D
    Davis, LW
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 61 (05): : 1385 - 1392
  • [42] Intensity-Modulated Radiation Therapy with Concurrent Carboplatin and Paclitaxel for Locally Advanced Head and Neck Cancer: Toxicities and Efficacy
    Vlacich, Gregory
    Diaz, Roberto
    Thorpe, Steven W.
    Murphy, Barbara A.
    Kirby, Fwyndee
    Sinard, Robert J.
    Shakhtour, Bashar
    Shyr, Yu
    Murphy, Patrick
    Netterville, James L.
    Yarbrough, Wendell G.
    Cmelak, Anthony J.
    ONCOLOGIST, 2012, 17 (05) : 673 - 681
  • [43] Comparison of intensity-modulated radiotherapy, adaptive radiotherapy proton radiotherapy, and adaptive proton radiotherapy for treatment of locally advanced head and neck cancer
    Simone, Charles B., II
    Ly, David
    Dan, Tu D.
    Ondos, John
    Ning, Holly
    Belard, Arnaud
    O'Connell, John
    Miller, Robert W.
    Simone, Nicole L.
    RADIOTHERAPY AND ONCOLOGY, 2011, 101 (03) : 376 - 382
  • [44] Impact of RBE variations on risk estimates of temporal lobe necrosis in patients treated with intensity-modulated proton therapy for head and neck cancer
    Engeseth, Grete May
    Hysing, Liv Bolstad
    Yepes, Pablo
    Pettersen, Helge Egil Seime
    Mohan, Radhe
    Fuller, Clifton Dave
    Stokkevag, Camilla Hanquist
    Wu, Richard
    Zhang, Xiaodong
    Frank, Steven Jay
    Gunn, Gary Brandon
    ACTA ONCOLOGICA, 2022, 61 (02) : 215 - 222
  • [45] Identification of Patient Benefit From Proton Therapy for Advanced Head and Neck Cancer Patients Based on Individual and Subgroup Normal Tissue Complication Probability Analysis
    Jakobi, Annika
    Bandurska-Luque, Anna
    Stuetzer, Kristin
    Haase, Robert
    Loeck, Steffen
    Wack, Linda-Jacqueline
    Moennich, David
    Thorwarth, Daniela
    Perez, Damien
    Luehr, Armin
    Zips, Daniel
    Krause, Mechthild
    Baumann, Michael
    Perrin, Rosalind
    Richter, Christian
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 92 (05): : 1165 - 1174
  • [46] Comparing cone- beam CT intensity correction methods for dose recalculation in adaptive intensity- modulated photon and proton therapy for head and neck cancer
    Kurz, Christopher
    Dedes, George
    Resch, Andreas
    Reiner, Michael
    Ganswindt, Ute
    Nijhuis, Reinoud
    Thieke, Christian
    Belka, Claus
    Parodi, Katia
    Landry, Guillaume
    ACTA ONCOLOGICA, 2015, 54 (09) : 1651 - 1657
  • [47] A matched-pair comparison of intensity-modulated radiation therapy with cetuximab versus intensity-modulated radiation therapy with platinum-based chemotherapy for locally advanced head neck cancer
    Huang, Jiayi
    Baschnagel, Andrew M.
    Chen, Peter
    Gustafson, Gregory
    Jaiyesmi, Ishmael
    Folbe, Mitchell
    Ye, Hong
    Akervall, Jan
    Krauss, Daniel
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2014, 19 (02) : 240 - 246
  • [48] Intensity-modulated radiation therapy for intermediate-risk prostate cancer: does ADT still have an impact in the dose-escalated external beam radiation therapy era?
    Soyano, Takashi
    Kozuka, Takuyo
    Kashihara, Kenichi
    Murakami, Yu
    Yonese, Junji
    Sasamura, Kazuma
    Shimoyachi, Nana
    Kashihara, Tairo
    Yoshioka, Yasuo
    Oguchi, Masahiko
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2023, 53 (06) : 514 - 521
  • [49] Assessment of dose gradient index variation during simultaneously integrated boost intensity-modulated radiation therapy for head and neck cancer patients
    Al-Rawi, Salam Abdulrazzaq Ibrahim
    Abouelenein, Hassan
    EL Nagdy, Mohamad El-Sayed
    Alabdei, Haidar Hamza
    Sulaiman, Awf Abdulrahman
    Al-Nuaimi, Dalya Saad
    Khalil, Magdy Mohammed
    Alshewered, Ahmed Salih
    PRECISION RADIATION ONCOLOGY, 2022, 6 (03): : 216 - 224
  • [50] Matched case-control study of quality of life and xerostomia after intensity-modulated radiotherapy or standard radiotherapy for head-and-neck cancer: Initial report
    Jabbari, S
    Kim, HM
    Feng, M
    Lin, A
    Tsien, C
    Elshaikh, M
    Terrel, JE
    Murdoch-Kinch, C
    Eisbruch, A
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 63 (03): : 725 - 731